IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Saudi Arabia biobanking market. The Saudi Arabia biobanking market size reached USD 611.1 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 748.6 Million by 2034, exhibiting a growth rate (CAGR) of 2.28% during 2026-2034 , driven by the rising prevalence of chronic diseases, Vision 2030 genomics and precision medicine programs, and growing demand for high-quality biological specimens.

Biobanking benefits from the long-horizon, infrastructure-led nature of healthcare research investment in Saudi Arabia, with every national genomics initiative, disease-research program, and targeted therapy pipeline requiring well-curated, clinically annotated biospecimens. The market is forecast to add USD 123.6 Million in incremental value between 2026 and 2034, with three structural forces shaping this trajectory: the growing burden of cancer, diabetes, and cardiovascular disorders, the Kingdom's push toward personalized medicine through genomics and proteomics, and deepening collaboration between academia, industry, and healthcare institutions.

Saudi Arabia Biobanking Market at a Glance:

  • Market Size (2025): USD 611.1 Million
  • Forecast Market Size (2034): USD 748.6 Million
  • CAGR (2026-2034): 2.28%
  • Specimen Types Covered: Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, and Others
  • Biobank Types Covered: Population-based Biobanks and Disease-oriented Biobanks
  • Key Demand Driver: Precision medicine and genomics research under Vision 2030

How AI is Reshaping the Future of the Saudi Arabia Biobanking Market

  • AI-Powered Biospecimen Data Analytics: Machine learning tools are being layered onto clinical, genomic, and demographic datasets linked to stored specimens, helping researchers identify biomarkers, stratify patient cohorts, and detect early disease signals faster than manual curation allows.
  • Automation and Robotics in Sample Management: Leading Saudi institutions are integrating robotics and automated storage systems into large-scale repositories, improving sample traceability, reducing handling errors, and supporting storage capacity for millions of biospecimens.
  • Integrated Genomic and Clinical Data Platforms: Biobanks are evolving from standalone tissue repositories into connected data platforms that link biological samples with genomic sequences and health records, strengthening Saudi Arabia's position in precision medicine and drug discovery.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-biobanking-market/requestsample

Saudi Arabia Biobanking Market Trends and Drivers:

The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is the foundational driver behind the market, generating sustained demand for diverse, high-quality biological specimens to understand disease mechanisms and develop targeted therapies. Advances in genomics and proteomics research are amplifying this need, as large-scale sample repositories become essential infrastructure for population-level studies, biomarker discovery, and the Kingdom's precision medicine ambitions.

Institutional expansion is compounding this research-led demand and supporting Saudi Arabia biobanking market growth. The Saudi Genome Program, launched in 2018 as a national Vision 2030 initiative, aims to build a genetic database for the Saudi population through 100,000 genomes, while the Saudi Biobank at King Abdullah International Medical Research Center holds more than 60,000 samples and was the first biobank in the Kingdom to receive ISO 20387 certification. King Faisal Specialist Hospital and Research Centre has also modernized its Biobank Center with capacity for 10 million biospecimens, reinforcing the infrastructure race underway across the Kingdom.

Collaboration and data sharing are reshaping how biobanks create value on top of these demand drivers. Joint initiatives between academia, industry, and healthcare institutions are accelerating research and improving access to high-quality biospecimens, while the Kingdom's National Biotechnology Strategy, which aims to position Saudi Arabia as a regional bioresearch hub by 2030, is encouraging further investment in clinical research capacity, pharma partnerships, and biobank governance standards.

Government Schemes and Vision 2030 Initiatives Driving Demand:

  • Saudi Genome Program: A flagship Vision 2030 initiative inaugurated in 2018 to build the first genetic map of Saudi society, targeting the analysis of 100,000 samples to support early diagnosis, preventive programs, and personalized treatment across the Kingdom.
  • National Biotechnology Strategy: A national roadmap aiming to position Saudi Arabia as a leading bioresearch and innovation hub in the region, supporting biobank accreditation, translational research, and local biotechnology capability.
  • Health Sector Transformation Program: A core Vision 2030 program emphasizing prevention, public health, and data-driven medical research, underpinning investment in biorepositories linked to anonymized patient and clinical data.
  • ISO 20387 Accreditation Push: Accreditation of institutions such as the Saudi Biobank under the international biobanking standard is raising quality benchmarks and improving the credibility of Saudi specimens for global research collaborations.
  • Clinical Research and Biotech Partnerships: Agreements such as the November 2025 MOU between KAIMRC and Flagship Pioneering to conduct early-phase trials of novel medicines in the Kingdom are expanding demand for well-characterized specimens and trial-ready research infrastructure.

Saudi Arabia Biobanking Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Specimen Type:

  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others

Specimen demand is shaped by the growing need for diverse, well-annotated biological materials across disease research and therapy development. Blood products and nucleic acid samples underpin genomic and biomarker studies, while solid tissue and cell lines support oncology research and targeted therapy development, with detailed segment-level size and forecast data covered in the full report.

Breakup By Biobank Type:

  • Population-based Biobanks
  • Disease-oriented Biobanks

Population-based biobanks collect specimens and clinical data from broad cohorts to study variations in health and disease across the Saudi population, while disease-oriented biobanks focus on specific conditions such as cancer, diabetes, and cardiovascular disorders to accelerate diagnostics and treatment research.

Breakup By Application:

  • Therapeutics
  • Research

Research applications span genetic studies, biomarker discovery, and precision medicine, while therapeutics applications use stored specimens to support the development of targeted treatments and personalized care pathways.

Breakup By End User:

  • Academic Institutions
  • Pharma and Biotech Companies

Academic institutions and research centers anchor demand through national genomics and disease-research programs, while pharma and biotech companies are increasingly engaging with Saudi biobanks through clinical research partnerships and translational studies.

Breakup By Region:

  • Northern and Central Region
  • Western Region
  • Eastern Region
  • Southern Region

Regional analysis covers all four major markets of the Kingdom, with the report assessing how research hospitals, genome centers, and academic institutions in each region contribute to specimen collection, storage, and demand growth through 2034.

Competitive Landscape:

The Saudi Arabia biobanking market is shaped by leading national research institutions and hospital-based repositories working alongside academic centers and emerging public-private partnerships. The report provides a comprehensive analysis of the competitive landscape, including market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant, along with detailed profiles of all major companies.

Prominent institutions shaping the Kingdom's biobanking ecosystem include the Saudi Biobank at King Abdullah International Medical Research Center, the King Faisal Specialist Hospital and Research Centre Biobank, and academic repositories such as the Biorepositories and Biospecimen Research Program at King Abdulaziz University, supported by national efforts such as the Saudi Genome Program.

Market Structure Analysis:

  • Institutional Leadership: National research centers and specialist hospitals anchor large-scale specimen collections, with ISO-accredited facilities setting quality benchmarks for the wider market
  • Collaboration Trend: Joint initiatives between academia, industry, and healthcare institutions are fostering data sharing and improving access to high-quality biospecimens
  • Capacity Expansion: Modernized, automation-enabled facilities with multi-million specimen capacity are intensifying the push toward integrated, data-linked biobank platforms

What Does The Full Report Cover?

If you are tracking the Saudi Arabia biobanking market for investment decisions, market entry planning, competitive benchmarking, or strategic advisory, IMARC Group's report gives you everything in one place:

  • Complete market sizing in value terms with historical data for 2020-2025 and forecasts covering the full 2026-2034 projection period
  • Industry catalysts and challenges analysis across specimen type, biobank type, application, end user, and regional markets
  • Sub-segment breakdowns for five specimen types, two biobank types, two applications, two end users, and four regions
  • Competitive landscape assessment covering market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant
  • Value chain analysis and Porter's five forces assessment covering new entrants, competitive rivalry, supplier power, buyer power, and threat of substitution
  • Latest trends covering precision medicine, genomics and proteomics research, AI-enabled specimen analytics, and collaborative biobanking initiatives shaping market competition across the Kingdom

Recent News and Developments in Saudi Arabia Biobanking Market

  • June 2026: Saudi Arabia's delegation to BIO International Convention 2026 launched the "Launch in Saudi" initiative to accelerate access to innovative therapies, while the Kingdom is set to host BIO Middle East from 14 to 16 December 2026, reflecting its growing role as a regional hub for health innovation and biotechnology.
  • November 2025: King Abdullah International Medical Research Center and Flagship Pioneering announced a strategic partnership to conduct early-phase clinical trials of novel medicines in Saudi Arabia, leveraging the center's ISO-accredited Saudi Biobank, which holds more than 60,000 samples.
  • January 2025: King Faisal Specialist Hospital and Research Centre announced the modernization of its Biobank Center, designed to store 10 million high-quality biospecimens including liquid biopsies, fresh tissue, and blood derivatives, in support of personalized medicine and Vision 2030 research goals.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

Key Questions This Report Answers

  • How has the Saudi Arabia biobanking market performed so far and how will it perform in the coming years?
  • What is the breakup of the Saudi Arabia biobanking market by specimen type, biobank type, application, and end user?
  • What are the key drivers and challenges in the Saudi Arabia biobanking market?
  • How is the rising prevalence of chronic diseases shaping demand for biospecimens in the Kingdom?
  • How are Vision 2030, the Saudi Genome Program, and the National Biotechnology Strategy reshaping the Saudi Arabia biobanking industry?
  • What are the various stages in the value chain of the Saudi Arabia biobanking market?
  • What is the structure of the market, who are the key players, and what is the degree of competition?

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: [email protected]

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Add as a preferred source on Google